Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Wntless promotes cellular viability and resistance to enzalutamide in castration-resistant prostate cancer cells.

Lombard AP, Liu C, Armstrong CM, D'Abronzo LS, Lou W, Evans CP, Gao AC.

Am J Clin Exp Urol. 2019 Aug 15;7(4):203-214. eCollection 2019.

2.

GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression.

Cucchiara V, Yang JC, Liu C, Adomat HH, Tomlinson Guns ES, Gleave ME, Gao AC, Evans CP.

Mol Cancer Ther. 2019 Oct;18(10):1811-1821. doi: 10.1158/1535-7163.MCT-18-1337. Epub 2019 Jul 24.

PMID:
31341032
3.

AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer.

Liu C, Yang JC, Armstrong CM, Lou W, Liu L, Qiu X, Zou B, Lombard AP, D'Abronzo LS, Evans CP, Gao AC.

Mol Cancer Ther. 2019 Oct;18(10):1875-1886. doi: 10.1158/1535-7163.MCT-18-1322. Epub 2019 Jul 15.

PMID:
31308078
4.

A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.

Jan YJ, Yoon J, Chen JF, Teng PC, Yao N, Cheng S, Lozano A, Chu GCY, Chung H, Lu YT, Chen PJ, Wang JJ, Lee YT, Kim M, Zhu Y, Knudsen BS, Feng FY, Garraway IP, Gao AC, Chung LWK, Freeman MR, You S, Tseng HR, Posadas EM.

Theranostics. 2019 Apr 13;9(10):2812-2826. doi: 10.7150/thno.34485. eCollection 2019.

5.

Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer.

Lombard AP, Liu C, Armstrong CM, D'Abronzo LS, Lou W, Chen H, Dall'Era M, Ghosh PM, Evans CP, Gao AC.

Transl Oncol. 2019 Jul;12(7):871-878. doi: 10.1016/j.tranon.2019.04.007. Epub 2019 May 7.

6.

IFNγ, a Double-Edged Sword in Cancer Immunity and Metastasis.

Liu C, Gao AC.

Cancer Res. 2019 Mar 15;79(6):1032-1033. doi: 10.1158/0008-5472.CAN-19-0083.

PMID:
30877097
7.

MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.

Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB.

Prostate Cancer Prostatic Dis. 2019 Feb 25. doi: 10.1038/s41391-019-0134-5. [Epub ahead of print]

PMID:
30804427
8.

Current strategies for targeting the activity of androgen receptor variants.

Armstrong CM, Gao AC.

Asian J Urol. 2019 Jan;6(1):42-49. doi: 10.1016/j.ajur.2018.07.003. Epub 2018 Sep 29. Review.

9.

In honor of Dr. Donald S. Coffey - Prostate cancer biology and therapy.

Gao AC, Mohler JL.

Asian J Urol. 2019 Jan;6(1):1-2. doi: 10.1016/j.ajur.2018.10.002. Epub 2018 Nov 3. No abstract available.

10.

Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer.

Liu C, Lou W, Yang JC, Liu L, Armstrong CM, Lombard AP, Zhao R, Noel ODV, Tepper CG, Chen HW, Dall'Era M, Evans CP, Gao AC.

Nat Commun. 2018 Nov 16;9(1):4700. doi: 10.1038/s41467-018-07178-x.

11.

What kind of patients with castration-naïve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysis.

Sun G, Zhang X, Chen J, Liao B, Liu Z, Zhao J, Gao AC, Yang Y, Shu K, Liu J, Zhao P, Shen P, Zeng H.

Urol Oncol. 2018 Dec;36(12):505-517. doi: 10.1016/j.urolonc.2018.09.005. Epub 2018 Oct 11.

PMID:
30316578
12.

KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC.

Wang HJ, Pochampalli M, Wang LY, Zou JX, Li PS, Hsu SC, Wang BJ, Huang SH, Yang P, Yang JC, Chu CY, Hsieh CL, Sung SY, Li CF, Tepper CG, Ann DK, Gao AC, Evans CP, Izumiya Y, Chuu CP, Wang WC, Chen HW, Kung HJ.

Oncogene. 2019 Jan;38(1):17-32. doi: 10.1038/s41388-018-0414-x. Epub 2018 Aug 2.

13.

Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer.

Lombard AP, Liu L, Cucchiara V, Liu C, Armstrong CM, Zhao R, Yang JC, Lou W, Evans CP, Gao AC.

Mol Cancer Ther. 2018 Oct;17(10):2197-2205. doi: 10.1158/1535-7163.MCT-17-1269. Epub 2018 Jun 11.

14.

Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with de novo bone metastatic prostate cancer.

Zhao J, Sun G, Liao B, Zhang X, Armstrong CM, Yin X, Liu J, Chen J, Yang Y, Zhao P, Tang Q, Wang Z, Chen Z, Li X, Wei Q, Li X, Chen N, Gao AC, Shen P, Zeng H.

BJU Int. 2018 Dec;122(6):994-1002. doi: 10.1111/bju.14398. Epub 2018 Jun 7.

PMID:
29772102
15.

Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.

Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV.

Eur Urol. 2018 May;73(5):715-723. doi: 10.1016/j.eururo.2017.11.038. Epub 2017 Dec 16. Review.

16.

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.

Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx118.

17.

Quercetin Targets hnRNPA1 to Overcome Enzalutamide Resistance in Prostate Cancer Cells.

Tummala R, Lou W, Gao AC, Nadiminty N.

Mol Cancer Ther. 2017 Dec;16(12):2770-2779. doi: 10.1158/1535-7163.MCT-17-0030. Epub 2017 Jul 20.

18.

ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.

Lombard AP, Liu C, Armstrong CM, Cucchiara V, Gu X, Lou W, Evans CP, Gao AC.

Mol Cancer Ther. 2017 Oct;16(10):2257-2266. doi: 10.1158/1535-7163.MCT-17-0179. Epub 2017 Jul 11.

19.

Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer.

Armstrong CM, Gao AC.

Asian J Urol. 2016 Oct;3(4):185-194. doi: 10.1016/j.ajur.2016.08.001. Epub 2016 Aug 22.

20.

Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.

Liu C, Armstrong CM, Lou W, Lombard AP, Cucchiara V, Gu X, Yang JC, Nadiminty N, Pan CX, Evans CP, Gao AC.

Mol Cancer Ther. 2017 Aug;16(8):1521-1530. doi: 10.1158/1535-7163.MCT-16-0912. Epub 2017 May 12.

21.

MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.

Armstrong CM, Liu C, Lou W, Lombard AP, Evans CP, Gao AC.

Prostate. 2017 Jun;77(9):1020-1028. doi: 10.1002/pros.23358.

22.

Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells.

Recouvreux MV, Wu JB, Gao AC, Zonis S, Chesnokova V, Bhowmick N, Chung LW, Melmed S.

Endocrinology. 2017 Jul 1;158(7):2255-2268. doi: 10.1210/en.2016-1939.

23.

Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy.

Cucchiara V, Yang JC, Mirone V, Gao AC, Rosenfeld MG, Evans CP.

Cancers (Basel). 2017 Jan 16;9(1). pii: E9. doi: 10.3390/cancers9010009. Review.

24.

CCN3-EZH2-AR feedback loop: new targets for enzalutamide and castration resistant prostate cancer.

Armstrong CM, Gao AC.

J Cell Commun Signal. 2017 Mar;11(1):89-91. doi: 10.1007/s12079-017-0378-6. Epub 2017 Mar 2.

25.

Induction of neuroendocrine differentiation in castration resistant prostate cancer cells by adipocyte differentiation-related protein (ADRP) delivered by exosomes.

Lin LC, Gao AC, Lai CH, Hsieh JT, Lin H.

Cancer Lett. 2017 Apr 10;391:74-82. doi: 10.1016/j.canlet.2017.01.018. Epub 2017 Jan 18.

PMID:
28109910
26.

Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.

Liu C, Armstrong CM, Lou W, Lombard A, Evans CP, Gao AC.

Mol Cancer Ther. 2017 Jan;16(1):35-44. doi: 10.1158/1535-7163.MCT-16-0186. Epub 2016 Oct 28.

27.

Corrigendum: ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer.

Wang J, Zou JX, Xue X, Cai D, Zhang Y, Duan Z, Xiang Q, Yang JC, Louie MC, Borowsky AD, Gao AC, Evans CP, Lam KS, Xu J, Kung HJ, Evans RM, Xu Y, Chen HW.

Nat Med. 2016 Jun 7;22(6):692. doi: 10.1038/nm0616-692b. No abstract available.

PMID:
27270780
28.

Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer.

Liu C, Armstrong C, Zhu Y, Lou W, Gao AC.

Oncotarget. 2016 May 31;7(22):32210-20. doi: 10.18632/oncotarget.8493.

29.

ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer.

Wang J, Zou JX, Xue X, Cai D, Zhang Y, Duan Z, Xiang Q, Yang JC, Louie MC, Borowsky AD, Gao AC, Evans CP, Lam KS, Xu J, Kung HJ, Evans RM, Xu Y, Chen HW.

Nat Med. 2016 May;22(5):488-96. doi: 10.1038/nm.4070. Epub 2016 Mar 28. Erratum in: Nat Med. 2016 Jun 7;22(6):692.

30.

Mechanisms of resistance in castration-resistant prostate cancer (CRPC).

Chandrasekar T, Yang JC, Gao AC, Evans CP.

Transl Androl Urol. 2015 Jun;4(3):365-80. doi: 10.3978/j.issn.2223-4683.2015.05.02. Review.

31.

Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation.

Tummala R, Nadiminty N, Lou W, Evans CP, Gao AC.

Prostate. 2016 Apr;76(5):445-55. doi: 10.1002/pros.23134. Epub 2015 Dec 30.

32.

Targeting molecular resistance in castration-resistant prostate cancer.

Chandrasekar T, Yang JC, Gao AC, Evans CP.

BMC Med. 2015 Sep 1;13:206. doi: 10.1186/s12916-015-0457-6. Review.

33.

Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies.

Armstrong CM, Gao AC.

Am J Clin Exp Urol. 2015 Aug 8;3(2):64-76. eCollection 2015. Review.

34.

Stat5a/b in Prostate Cancer Metastasis.

Gao AC, Zhu Y.

Am J Pathol. 2015 Sep;185(9):2351-3. doi: 10.1016/j.ajpath.2015.06.002. Epub 2015 Jul 15.

PMID:
26187549
35.

NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer.

Nadiminty N, Tummala R, Liu C, Lou W, Evans CP, Gao AC.

Mol Cancer Ther. 2015 Aug;14(8):1884-95. doi: 10.1158/1535-7163.MCT-14-1057. Epub 2015 Jun 8.

36.

Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.

Zhu Y, Liu C, Armstrong C, Lou W, Sandher A, Gao AC.

Clin Cancer Res. 2015 Sep 15;21(18):4133-42. doi: 10.1158/1078-0432.CCR-15-0269. Epub 2015 May 20.

37.

Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition.

Liu C, Lou W, Armstrong C, Zhu Y, Evans CP, Gao AC.

Prostate. 2015 Sep;75(13):1341-53. doi: 10.1002/pros.23015. Epub 2015 May 13.

38.

Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.

Liu C, Lou W, Zhu Y, Yang JC, Nadiminty N, Gaikwad NW, Evans CP, Gao AC.

Cancer Res. 2015 Apr 1;75(7):1413-22. doi: 10.1158/0008-5472.CAN-14-3080. Epub 2015 Feb 3.

39.

Synthesis of carbon-11-labeled aminoalkylindole derivatives as new candidates of cannabinoid receptor radioligands for PET imaging of alcohol abuse.

Gao M, Gao AC, Wang M, Zheng QH.

Bioorg Med Chem Lett. 2014 Dec 15;24(24):5581-5586. doi: 10.1016/j.bmcl.2014.10.097. Epub 2014 Nov 6.

PMID:
25466179
40.

Zoledronic acid at the time of castration prevented castration-induced bone metastasis in mice.

Ghosh PM, Gao AC.

Endocr Relat Cancer. 2014 Oct;21(5):C11-4. doi: 10.1530/ERC-14-0387. Epub 2014 Sep 2.

PMID:
25183429
41.

Simple synthesis of new carbon-11-labeled 1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives for PET imaging of A₃ adenosine receptor.

Gao M, Gao AC, Wang M, Zheng QH.

Appl Radiat Isot. 2014 Sep;91:71-8. doi: 10.1016/j.apradiso.2014.05.005. Epub 2014 May 21.

PMID:
24908190
42.

Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST).

Zhu Y, Liu C, Cui Y, Nadiminty N, Lou W, Gao AC.

Prostate. 2014 Aug;74(11):1086-94. doi: 10.1002/pros.22819. Epub 2014 May 12.

PMID:
24819501
43.

Expression, characterization, and improvement of a newly cloned halohydrin dehalogenase from Agrobacterium tumefaciens and its application in production of epichlorohydrin.

Liu ZQ, Gao AC, Wang YJ, Zheng YG, Shen YC.

J Ind Microbiol Biotechnol. 2014 Jul;41(7):1145-58. doi: 10.1007/s10295-014-1443-2. Epub 2014 Apr 29.

PMID:
24777710
44.

Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.

Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao AC.

Clin Cancer Res. 2014 Jun 15;20(12):3198-3210. doi: 10.1158/1078-0432.CCR-13-3296. Epub 2014 Apr 16. Erratum in: Clin Cancer Res. 2017 Jan 1;23 (1):323.

45.

Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model.

Nguyen HG, Yang JC, Kung HJ, Shi XB, Tilki D, Lara PN Jr, DeVere White RW, Gao AC, Evans CP.

Oncogene. 2014 Sep 4;33(36):4521-30. doi: 10.1038/onc.2014.25. Epub 2014 Mar 24.

46.

Upregulation of glucose metabolism by NF-κB2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells.

Cui Y, Nadiminty N, Liu C, Lou W, Schwartz CT, Gao AC.

Endocr Relat Cancer. 2014 May 6;21(3):435-42. doi: 10.1530/ERC-14-0107. Print 2014 Jun.

47.

Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model.

Qu S, Wang K, Xue H, Wang Y, Wu R, Liu C, Gao AC, Gout PW, Collins CC, Wang Y.

Mol Oncol. 2014 Mar;8(2):311-22. doi: 10.1016/j.molonc.2013.12.004. Epub 2013 Dec 15.

48.

Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells.

Liu C, Zhu Y, Lou W, Cui Y, Evans CP, Gao AC.

Prostate. 2014 Feb;74(2):201-9. doi: 10.1002/pros.22741. Epub 2013 Oct 16.

49.

RhoGDIα downregulates androgen receptor signaling in prostate cancer cells.

Zhu Y, Liu C, Tummala R, Nadiminty N, Lou W, Gao AC.

Prostate. 2013 Nov;73(15):1614-22. doi: 10.1002/pros.22615. Epub 2013 Aug 6.

50.

Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer.

Zhu Y, Liu C, Nadiminty N, Lou W, Tummala R, Evans CP, Gao AC.

Mol Cancer Ther. 2013 Sep;12(9):1829-36. doi: 10.1158/1535-7163.MCT-13-0208. Epub 2013 Jul 16.

Supplemental Content

Support Center